p110δ in 1

Compound P110 (Drp1 peptide inhibitor P110) is a selective Drp1 peptide inhibitor with neuroprotective effects. It inhibits the activation of Drp1, prevents Drp1 mitochondrial translocation induced by MPTP, and alleviates dopamine neuron loss, dopaminergic terminal damage, and behavioral deficits caused by MPTP. This compound is useful for Alzheimer's disease research. Additionally, Compound P110 reduces mitochondrial and organ damage in animal models of Huntington's disease, cerebral ischemia, and myocardial infarction.

Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent PI3Kα inhibitor (IC₅₀ = 5 nM) with selectivity and oral bioavailability, exhibiting activity against PI3Kβ/γ/δ that is dozens of times weaker than against PI3Kα (IC₅₀ = 250/290/1200 nM). Alpelisib exhibits targeting activity against PIK3CA-mutated tumors and may be utilized in cancer research.

P110δ-IN-1 (PWT-143) is an effective and selective inhibitor of P110δ (IC50: 8.4 nM).

PI3K-IN-51, characterized as a PI3K inhibitor, exhibits IC50 values below 500 nM for p120γ and p110δ/p85α (WO2016204429A1; Example 10) [1].